You are here

Prices & Quotes - UK Markets - Health Care Equipment & Services (4530)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Down 7,670.94
Change Today:

Novacyt swings to first-half loss amid DHSC dispute

By Josh White

Date: Monday 27 Sep 2021

LONDON (ShareCast) - (Sharecast News) - Clinical diagnostics specialist Novacyt reported group consolidated unaudited revenue of 54m in its first half on Monday, down from 63.3m year-on-year, which excluded 40.8m of Department of Health and Social Care (DHSC) revenues, while that contract dispute continued.
The AIM-traded firm said non-DHSC revenue increased 20% for the six months ended 30 June, to 54m from 44.8m, supported by the growing UK private testing market.

It said it booked exceptional cost-of-sales of 35.8m in connection with the DHSC contract dispute, to write-down inventory and terminate supply agreements that it had built in anticipation of further DHSC demand, and to book the cost of products supplied to the DHSC in 2021 that had not been paid for.

The group's gross margin before exceptional items was 71%, delivering a gross profit of 38m.

After the exceptional DHSC-related cost of sales, Novacyt's gross margin dropped to 4%, delivering a gross profit of 2.3m.

Group adjusted EBITDA totalled 23.2m before exceptionals, down from 43.1m in the first half of 2020.

Novacyt reported an operating loss of 13.6m, swinging from a profit of 42.2m year-on-year, driven by the one-time exceptional cost of sales and stock write-down, while its loss after tax totalled 12.7m, compared to a profit of 35.1m a year earlier.

Cash at 30 June totalled 77.2m, with nil debt.

"During 2021, Novacyt has remained at the forefront in its response to the constantly changing global Covid-19 pandemic," said group chief executive officer Graham Mullis.

"We have launched 18 new Covid-19 products since the beginning of 2021 and we expect Novacyt to continue to play a major role in Covid-19 testing well into 2022.

"We also remain focused on strengthening our long-term position and executing against our strategy by building our product and instrument platforms and expanding our commercial infrastructure for growth beyond Covid-19."

At 0823 BST, shares in Novacyt were down 4.17% at 298.71p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.


Price Data

Price 7,670.94
Change Today -126.70
03-Dec-21 Close 7,670.94

Top Risers

Price Change
Feedback 0.90p +12.5%
Surgical Innovations Group 2.40p +6.7%
Open Orphan 21.00p +6.1%
Abingdon Health 30.00p +5.3%
Induction Healthcare Group 55.00p +4.8%
Genedrive 40.50p +2.3%
Omega Diagnostics Group 26.50p +1.9%
Circassia Group 37.70p +1.9%
Kromek Group 13.00p +1.0%
CareTech Holding 572.00p +0.4%

Top Fallers

Price Change
MyHealthchecked 2.45p -3.9%
Novacyt S.A. (CDI) 352.30p -3.4%
Medica Group 160.00p -3.0%
Craneware 2,400.00p -2.8%
Integrated Diagnostics Holdings $1.29 -2.6%
Diaceutics 101.00p -2.4%
Mediclinic International 291.60p -2.2%
Polarean Imaging 55.00p -1.8%
Cambridge Cognition Holdings 121.50p -1.6%
Intelligent Ultrasound Group 16.75p -1.5%